ARMATA PHARMACEUTICALS, INC. Revenue from Contract with Customer, Including Assessed Tax
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Revenue from Contract with Customer, Including Assessed Tax of $31.00 thousand for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-08-13.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2020-08-13
- ARMATA PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2020-06-30 was $31.00K.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month |
|---|---|---|
| 2020-06-30 | $31.00K 10-Q · filed 2020-08-13 | $31.00K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |